Discovery Award Winner

About this entry

Drugs & Diagnostic for Tropical Diseases (DDTD) specializes in affordable diagnostics to detect infectious diseases in low-resource settings. We develop Lateral Flow Immunoassays, which are diagnostic devices based on the same format as the consumer pregnancy test, and are ideal for use in the field and at the point of care. We offer novel ultra-high contrast reporter nanoparticles to increase the analytical sensitivity of Lateral Flow Immunoassays. We have experience with the economic and logistic challenges to develop such devices for low-income populations, and are funneling this experience to propose an affordable platform to triage superbugs. DDTD is a start-up registered as a 501(c)(3) non-profit research organization. 

Our test will be used at the point-of-care to determine rapidly and with a minimal budget if ciprofloxacin will be effective to treat a given infection. The test relies on a lateral flow platform, similar to a home pregnancy test, and utilizes novel plasmonic nanoparticles for high analytical sensitivity. The test detects a binding event between ciprofloxacin and its bacterial target. Because binding events are so rapid, the test can therefore be completed within minutes without waiting for 24-48 hours as in a standard drug susceptibility test. We are currently demonstrating proof-of-concept with DNA gyrase isolated from E. Coli. Moving forward, we will adapt the test to other bacteria.

If you would like to be introduced to this team for collaboration, get in touch with the Longitude prize.